Last reviewed · How we verify

Granata Bio Corporation — Portfolio Competitive Intelligence Brief

Granata Bio Corporation pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
hMG subcutaneous injection hMG subcutaneous injection phase 3 Growth hormone Growth hormone receptor Endocrinology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Changchun GeneScience Pharmaceutical Co., Ltd. · 1 shared drug class
  3. Merck KGaA, Darmstadt, Germany · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Granata Bio Corporation:

Cite this brief

Drug Landscape (2026). Granata Bio Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/granata-bio-corporation. Accessed 2026-05-16.

Related